Download PDF
Thromb Haemost 1996; 76(04): 541-544
DOI: 10.1055/s-0038-1650619
Original Article
Schattauer GmbH Stuttgart

A Pilot Study on Bolus Administration of Recombinant Staphylokinase for Coronary Artery Thrombolysis

S Vanderschueren
The Center for Molecular and Vascular Biology, University of Leuven, Unit of Cardiology, University Hospitals, Leuven, Belgium
,
D Collen
The Center for Molecular and Vascular Biology, University of Leuven, Unit of Cardiology, University Hospitals, Leuven, Belgium
,
F Van de Werf
The Center for Molecular and Vascular Biology, University of Leuven, Unit of Cardiology, University Hospitals, Leuven, Belgium
› Author Affiliations
Further Information

Publication History

Received 29 January 1996

Accepted after resubmission 21 June 1996

Publication Date:
10 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Recombinant staphylokinase (Sak) is a highly fibrin-specific thrombolytic agent but the optimal dose and mode of administration remain to be defined. Intravenous (i.v.) infusion over 5 min of 20 mg Sak in 12 patients with acute myocardial infarction induced complete coronary patency (TIMI perfusion grade 3) in 7 patients (58%) within 60 min. In 3 of the 5 patients with no or suboptimal flow (TIMI grade 0,1 or 2) at 60 min, an additional 10 mg i.v. bolus of Sak resulted in TIMI grade 3 flow at 90 min. No major treatment-related complication occurred. Residual fibrinogen and α2-antiplasmin levels at 90 min were 110 ± 6.0% and 98 ±4.1% (mean ± SEM) of baseline, respectively. Median antibody-related Sak-neutralizing activity was low at baseline (0.0 μg/ml) and after 1 week (0.5 μg/ml) but increased from day 10 on (to 4.0 μg/ml).

Thus, bolus thrombolysis with Sak may induce efficient coronary artery recanalization while preserving circulating fibrinogen and α2-antiplasmin. Comparative trials of coronary thrombolysis with double-bolus Sak appear to be warranted.

 

  • References

  • 1 Anderson HV, Willerson JT. Current concepts: thrombolysis in acute myocardial infarction. N Engl J Med 1993; 329: 703-709
    CrossrefPubMedGoogle Scholar
  • 2 Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989; 14: 1566-1569
    CrossrefPubMedGoogle Scholar
  • 3 The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
    PubMedGoogle Scholar
  • 4 The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622
    PubMedGoogle Scholar
  • 5 Agnelli G. Rationale for bolus t-PA therapy to improve efficacy and safety. Chest 1990; 97: 161S-167S
    CrossrefPubMedGoogle Scholar
  • 6 Purvis JA. Novel and innovative dosing regimens in thrombolytic therapy for acute myocardial infarction. J Thromb Thrombol 1995; 1: 145-151
    CrossrefPubMedGoogle Scholar
  • 7 Goldhaber SZ. Bolus and accelerated thrombolysis. Experimental observations and clinical management of myocardial infarction and pulmonary embolism. Chest 1995; 107: 889-892
    PubMedGoogle Scholar
  • 8 Becker RC. Achieving optimal reperfusion without adjunctive antithrombotic therapy: novel thrombolytic dosing strategies. J Thromb Thrombol 1995; 1: 269-277
    CrossrefPubMedGoogle Scholar
  • 9 Eisert WG. Bolus treatment regimen of rt-PA determines the rate and extent of fibrinolysis of identical doses in infusion therapy. Blood 1987; 70 (Suppl. 01) 370A
    PubMedGoogle Scholar
  • 10 Cercek B, Lew AS, Yano J, Reddy KNN, Ganz W. Thrombolytic effect of recombinant tissue-type plasminogen activator administered as a bolus. Clin Res 1987; 35: 102A
    PubMedGoogle Scholar
  • 11 Clozel J-P, Tschopp T, Luedin E, Holvoet P. Time course of thrombolysis induced by intravenous bolus or infusion of tissue plasminogen activator in a rabbit jugular vein thrombolysis model. Circulation 1989; 79: 125-133
    CrossrefPubMedGoogle Scholar
  • 12 Purvis JA, McNeill AJ, Siddiqui RA, Roberts MJ, McClements BM, McEneaney D, Campbell NPS, Khan MM, Webb SW, Wilson CM, Adgey AAJ. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. J Am Coll Cardiol 1994; 23: 6-10
    CrossrefPubMedGoogle Scholar
  • 13 Collen D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential?. Blood 1994; 84: 680-686
    PubMedGoogle Scholar
  • 14 Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-1853
    CrossrefPubMedGoogle Scholar
  • 15 Schlott B, Hartmann M, Gührs KH, Birch-Hirschfeld E, Pohl HD, Vanderschueren S, Van de Werf F, Michoel A, Collen D, Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. BioTechnology 1994; 12: 185-189
    CrossrefPubMedGoogle Scholar
  • 16 Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, Van de Werf F. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-2049
    CrossrefPubMedGoogle Scholar
  • 17 Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe R, Vermylen J, Collen D. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995; 92: 2050-2057
    CrossrefPubMedGoogle Scholar
  • 18 Gase A, Birch-Hirschfeld E, Gührs K-H, Hartmann M, Vetterman S, Damaschun G, Damaschun H, Gast K, Misselwitz R, Zinver D, Collen D, Schlott B. The thermostability of natural variants of bacterial plasminogen-activator staphylokinase. Eur J Biochem 1994; 223: 303-308
    CrossrefPubMedGoogle Scholar
  • 19 Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobek BE, Willerson J, Williams DO, Zaret BK, Braunwald E. Thrombolysis in Myocardial Infarction (T1MI) trial, phase 1: a comparison between i.v. tissue plasminogen activator and i.v. streptokinase: clinical findings through hospital discharge. Circulation 1987; 76: 142-154
    CrossrefPubMedGoogle Scholar
  • 20 Declerck PJ, Vanderschueren S, Billiet J, Moreau H, Collen D. Prevalence and induction of circulating antibodies against recombinant staphylokinase. Thromb Haemost 1994; 71: 129-133
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Sobel BE, Nachowiak DA, Fry ETA, Bergmann SR, Torr SR. Paradoxical attenuation of fibrinolysis attributable to “plasminogen steal” and its implications for coronary thrombolysis. Coron Art Dis 1990; 1: 111-119
    CrossrefPubMedGoogle Scholar
  • 22 Eisenberg PR. Procoagulant effects of fibrinolytic agents. In: Coronary Thrombolysis in Perspective. Principles Underlying Conjunctive and Adjunctive Therapy Sobel BE, Collen D. (eds) Marcel Dekker Inc; Basel: 1993: 77-99
  • 23 Vanderschueren SMF, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost 1994; 72: 297-301
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Dehmer GJ, Gresalfi N, Daly D, Oberhardt B, Tate DA. Impairment of fibrinolysis by streptokinase, urokinase and recombinant tissue-type plasminogen activator in the presence of radiographic contrast agents. J Am Coll Cardiol 1995; 25: 1069-1075
    CrossrefPubMedGoogle Scholar